Navigation Links
RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer

PROVIDENCE -- Rhode Island Hospital is one of only four sites across the country to participate in a new clinical trial called the DIGNITY Study. The study will investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in conjunction with mild hyperthermia (a form of heat therapy) for treating recurrent chest wall breast cancer.

Recurrent chest wall (RCW) breast cancer is a return of breast cancer on the chest wall, most commonly presenting in the skin overlying the mastectomy scar, affecting approximately 20,000 to 30,000 women each year in the United States. Following a mastectomy, RCW disease will usually present as a small lump in the mastectomy scar or under the skin of the chest or abdominal area. It may be visible or can be felt under the skin, and often goes undetected for some time as it may be mistaken for a leftover stitch or scar tissue from the mastectomy surgery. A significant number of women who are diagnosed with RCW disease frequently cannot be treated with further surgery, radiation or chemotherapy because their available treatment options have been exhausted. As a result, these women often face a poor prognosis.

Rhode Island Hospital is the only hospital in New England to participate in the DIGNITY study that will test 100 patients nationally with an encapsulated chemotherapeutic agent called ThermoDox combined with hyperthermia treatment. ThermoDox is a heat-activated version of an approved and frequently used oncology drug for the treatment of a wide range of cancers, including breast cancer.

Rhode Island Hospital was the first to enroll and treat a patient. That patient has undergone the first three of a 6-cycle course of treatment. Brigid O'Connor, MD, PhD, a radiation oncologist at Rhode Island Hospital, is the principal investigator for the trial in Rhode Island.

According to O'Connor, "We treated our first patient recently and she tolerated the procedure well. I am excited to see her response to this new treatment." She continues, "The rapid development of ThermoDox is warranted so we can provide these women who are experiencing recurrent chest wall cancer with a better treatment for this devastating disease. We look forward to the outcomes of this trial in the hope of gaining increased local tumor control and improved quality of life for our patients."

To be eligible for participation in the trial, patients must have a confirmed diagnosis of RCW disease, had prior radiation to their chest wall and received two chemotherapy regimens.


Contact: Nancy Jean

Related medicine news :

1. Maryjane A. Wurth Named New President of Illinois Hospital Association
2. l.a. Hospitals Struggle for Emergency Room Care, Pay Physicians High Fees for On-Call Coverage
3. reThinking eHealth Webinar Announced: Hospital Marketing in the eHealth Era
4. Senators Baucus and Grassley Statement Regarding Physician Hospitals Despicable
5. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
6. Baylor Dallas Recognized In U.S. News Media Groups 2009 - 2010 Americas Best Hospitals
7. Auroras Milwaukee Hospitals Recognized in US News and World Report
8. The Mount Sinai Medical Center Named to "Honor Roll" in U.S. News's 2009-10 Edition of America's Best Hospitals
9. Northwestern Memorial Among Americas Best Hospitals in 11 Clinical Specialties According to U.S. News 2009 Rankings
10. Ochsner Medical Center, Only Louisiana Hospital Listed in Americas Best by U.S. News
11. National Jewish Health Named Top Respiratory Hospital for 12th Consecutive Year
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... heating products business. Cozy Products explains what this means for business moving forward. , ... the Cozy Products business model: to sell personal heaters that reduce energy consumption, are ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... , ... Since its launch in 2012, the Regenestem brand ... therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent and ... , Organizations are required to hold a registered trademark in order to make ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
Breaking Medicine Technology: